Previous 10 | Next 10 |
Gainers: Kiniksa Pharmaceuticals (KNSA) +18%, Humanigen (HGEN) +15%, Neuronetics (STIM) +16%, American Well (AMWL) +13%, Xtant Medical (XTNT) +5%.Losers: Corbus Pharmaceuticals (CRBP) -39%, Axovant Gene Therapies (AXGT)-20%, Iovance Bioth...
Corbus Pharmaceuticals CRBP -31% as lenabasum flunks mid-stage cystic fibrosis study.Iovance Biotherapeutics IOVA -20% as it has not reached agreement with the FDA on the required potency assays to fully define its tumor-infiltrating lymphocyte therapy lifileucel...
4 Penny Stocks Trading Higher This Week If you’ve begun putting together a list of penny stocks this week , price levels might be a focus of yours. Are you looking for stocks under 10 cents or are you looking for higher-price penny socks? You’ve got a wide range to...
Artelo Biosciences (ARTL) receives UK's ethics committee approval for its Cancer Appetite Recovery Study (CAReS) trials of the synthetic cannabinoid ART27.13 in patients with cancer anorexia and weight loss. CAReS is a Phase 1/2 clinical trial of ART27.13, which will enroll up to 49 subj...
LA JOLLA, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced the receipt of Ethics Committee approval in...
LA JOLLA, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C. Wainwright Annual Global In...
LA JOLLA, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer and Andy Yates, Ph...
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...
LA JOLLA, CA / ACCESSWIRE / August 26, 2020 / Artelo Biosciences, Inc. (NASDAQ:ARTL) , a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the LD 500 Virtual Investor conference being ...
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. "For the first time in ten years, we were unable to host our mid-year conference, which ...
News, Short Squeeze, Breakout and More Instantly...
Artelo Biosciences Inc. Company Name:
ARTL Stock Symbol:
OTCMKTS Market:
Artelo Biosciences Inc. Website:
ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment Phase 1 trial results expected in the first half of 2025 SOLANA BEACH, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- A...
SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological condit...
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a c...